Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 2/2018

01-12-2018 | Research Article

The interaction of dyslipidaemia with glycaemia in an adult population study

Authors: Sarah Cuschieri, Josanne Vassallo, Neville Calleja, Christopher Barbara, Julian Mamo

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2018

Login to get access

Abstract

Purpose

Individuals with dysglycaemic are prone to dyslipidaemia. Understanding the dyslipidaemic status of dysglycaemic individuals is essential for monitoring and early prevention. The aim was to assess the control of lipidaemia by glycaemic status in a representative adult population.

Methods

A retrospective health examination survey was performed on a sample of adults (n = 3947) in Malta in 2014–6. Sociodemographic data, biochemistry blood tests and anthropometric measurements were gathered. Statistical analysis was performed to evaluate the lipidaemic status and its control across the glycaemic spectrum (normoglycemic, impaired fasting glucose individuals, new diabetics and known diabetics).

Results

The prevalence of uncontrolled dyslipidaemia was 7.75% (CI 95%: 6.69–8.63), among whom 6.97% (CI 95%: 6.21–7.81) were naïve dyslipidaemic. A progressive elevation in both LDL-C and total cholesterol but not triglycerides was present among uncontrolled dyslipidaemia individuals across the glycaemic spectrum. Global dyslipidaemia was present in 19.26% (CI 95%: 18.05–20.52) of the total general population and in 46.59% (CI 95%: 40.49–52.69%) of known diabetics. Most individuals irrespective of lipid status were normoglycaemic.

Conclusions

Dyslipidaemia occurs in the presence of insulin resistance. Dyslipidaemia predominated in the normoglycaemic state irrespective of statins use, indicating the need to manage dyslipidaemia prior to dysglycaemia.
Literature
1.
go back to reference Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73:327–39.CrossRefPubMed Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73:327–39.CrossRefPubMed
2.
go back to reference Samatha P, Venkateswarlu MSPV. Lipid profile levels in type 2 diabetes mellitus from the tribal population of Adilabad in Andhra Pradesh, India. J Clin diagnostic Res. 2012;6:590–2. Samatha P, Venkateswarlu MSPV. Lipid profile levels in type 2 diabetes mellitus from the tribal population of Adilabad in Andhra Pradesh, India. J Clin diagnostic Res. 2012;6:590–2.
3.
4.
go back to reference Inzucchi SE, Amatruda JM. Lipid management in patients with diabetes: translating guidelines into action. Diabetes Care. 2003;26:1309–11.CrossRefPubMed Inzucchi SE, Amatruda JM. Lipid management in patients with diabetes: translating guidelines into action. Diabetes Care. 2003;26:1309–11.CrossRefPubMed
5.
go back to reference Solano MP, Goldberg RB. Lipid Management in Type 2 Diabetes. Clin Diabetes. 2006;24:27–32.CrossRef Solano MP, Goldberg RB. Lipid Management in Type 2 Diabetes. Clin Diabetes. 2006;24:27–32.CrossRef
6.
go back to reference Ali F, Jamil H, Anwar SS, Wajid N. Characterization of lipid parameters in diabetic and non-diabetic atherosclerotic patients. J Geriatr Cardiol. 2015;12:37–43.PubMedCentralPubMed Ali F, Jamil H, Anwar SS, Wajid N. Characterization of lipid parameters in diabetic and non-diabetic atherosclerotic patients. J Geriatr Cardiol. 2015;12:37–43.PubMedCentralPubMed
7.
go back to reference Barrett-Connor E, Grundy SM, Holdbrook MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol. 1982;115:657–63.CrossRefPubMed Barrett-Connor E, Grundy SM, Holdbrook MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol. 1982;115:657–63.CrossRefPubMed
8.
go back to reference Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Investig. 1999;29(Suppl 2):12–6.CrossRef Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Investig. 1999;29(Suppl 2):12–6.CrossRef
9.
go back to reference Daniel MJ. Lipid management in patients with type 2 diabetes. Am Heal drug benefits. 2011;4:312–22. Daniel MJ. Lipid management in patients with type 2 diabetes. Am Heal drug benefits. 2011;4:312–22.
10.
go back to reference Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Rev Port Cardiol. 2006;25:865–8. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Rev Port Cardiol. 2006;25:865–8.
11.
go back to reference Cholesterol Treatment Trialists’ (CTT), Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.CrossRefPubMedCentral Cholesterol Treatment Trialists’ (CTT), Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.CrossRefPubMedCentral
12.
go back to reference Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003;99:95–112.CrossRefPubMed Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003;99:95–112.CrossRefPubMed
14.
go back to reference Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering--are they clinically relevant? Eur Heart J. 2003;24:225–48.CrossRefPubMed Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering--are they clinically relevant? Eur Heart J. 2003;24:225–48.CrossRefPubMed
15.
17.
go back to reference Cuschieri S, Malta MJ. Mediterranean diabetes hub – A journey through the years. Malta Med J. 26. Cuschieri S, Malta MJ. Mediterranean diabetes hub – A journey through the years. Malta Med J. 26.
20.
go back to reference Hockley T, Gemmill M. European Cholesterol Guidelines Report https://policy-centre.com/wp-content/uploads/2017/04/European-Cholesterol-Guidelines07.pdf (accessed 5 November 2017). Hockley T, Gemmill M. European Cholesterol Guidelines Report https://​policy-centre.​com/​wp-content/​uploads/​2017/​04/​European-Cholesterol-Guidelines07.​pdf (accessed 5 November 2017).
21.
go back to reference Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.CrossRefPubMed Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.CrossRefPubMed
22.
go back to reference American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2016; 39 Suppl 1: S13–S22. American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2016; 39 Suppl 1: S13–S22.
23.
go back to reference WHO. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Heal Organ. 2013:102. WHO. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Heal Organ. 2013:102.
25.
26.
go back to reference Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001;86:965–71.CrossRefPubMed Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001;86:965–71.CrossRefPubMed
27.
go back to reference Taskinen M-R, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239:483–95.CrossRefPubMed Taskinen M-R, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239:483–95.CrossRefPubMed
28.
go back to reference Haffner SM, Mykkänen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975–80.CrossRefPubMed Haffner SM, Mykkänen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975–80.CrossRefPubMed
29.
go back to reference Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368:1–19.CrossRefPubMed Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368:1–19.CrossRefPubMed
30.
31.
32.
go back to reference Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia. 2013;56:686–95.CrossRefPubMed Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia. 2013;56:686–95.CrossRefPubMed
34.
go back to reference Vanelli M, Pedan A, Liu N, Hoar J, Messier D, Kiarsis K. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther. 2009;31:2628–52.CrossRefPubMed Vanelli M, Pedan A, Liu N, Hoar J, Messier D, Kiarsis K. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther. 2009;31:2628–52.CrossRefPubMed
35.
go back to reference Zullig L, Gellad W, Moaddeb J, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015;9:139.CrossRefPubMedCentralPubMed Zullig L, Gellad W, Moaddeb J, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015;9:139.CrossRefPubMedCentralPubMed
36.
go back to reference American Diabetes Association AD. 4. Lifestyle Management. Diabetes Care. 2017;40:S33–43.CrossRef American Diabetes Association AD. 4. Lifestyle Management. Diabetes Care. 2017;40:S33–43.CrossRef
37.
go back to reference Thunander Sundbom L, Bingefors K. Women and men report different behaviours in, and reasons for medication non-adherence: a nationwide Swedish survey. Pharm Pract (Granada). 2012;10:207–21.CrossRef Thunander Sundbom L, Bingefors K. Women and men report different behaviours in, and reasons for medication non-adherence: a nationwide Swedish survey. Pharm Pract (Granada). 2012;10:207–21.CrossRef
38.
go back to reference Chen S-L, Lee W-L, Liang T, Liao IC. Factors associated with gender differences in medication adherence: a longitudinal study. J Adv Nurs. 2014;70:2031–40.CrossRefPubMed Chen S-L, Lee W-L, Liang T, Liao IC. Factors associated with gender differences in medication adherence: a longitudinal study. J Adv Nurs. 2014;70:2031–40.CrossRefPubMed
Metadata
Title
The interaction of dyslipidaemia with glycaemia in an adult population study
Authors
Sarah Cuschieri
Josanne Vassallo
Neville Calleja
Christopher Barbara
Julian Mamo
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2018
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-018-0377-z

Other articles of this Issue 2/2018

Journal of Diabetes & Metabolic Disorders 2/2018 Go to the issue